VIDEO: Macular telangiectasia type 2 cell therapy shows promising 9-year data
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Mark Gillies, MD, PhD, of the Save Sight Institute in Sydney, Australia, discusses positive safety and efficacy data for NT-501 for macular telangiectasia type 2.
NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals), an encapsulated cell therapy, was well tolerated overall and showed promise in reducing ellipsoid zone loss.
“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well tolerated and that the efficacy appears to persist up until that time point,” Gillies said.
The Prescription Drug User Fee Act date for the biologics license application for NT-501 is March 18, 2025, as Healio previously reported.
Collapse
Gilles M. Long-term safety and efficacy of revakinagene taroretcel (NT-501) ciliary neurotrophic factor implant for macular telangiectasia type 2. Presented at: Retina 2025; Jan. 18-24, 2025; Koloa, Hawaii.
Read more about